Selected Publications
Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV.: Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies Transplant Cell Ther : 2023.
Christopher Snyder & Saar Gill: Good CARMA: Turning bad tumor-resident myeloid cells good with chimeric antigen receptor macrophages Immunol Rev. : 2023.
Rohtesh S Mehta 1, Haris Ali 2, Yang Dai 3, Bert Yao 3, Bethany Overman 4, Voravit Ratanatharathorn 5, Saar Gill 6, Gerard Socié 7, Kevin Anderson 3, Jean Yves Cahn 8, Arshad Mujeebuddin 3, Richard Champlin 4, Elizabeth Shpall 4, Shernan G Holtan 9, Amin Alousi: A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement Bone Marrow Transplant : 2023.
Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW: Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol. : 2023.
Katherine Cummins & Saar Gill: Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia Hematol Oncol Clin North Am. : 2023.
Welty NE, Gill SI.: Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review JACC CardioOncol 4 : 563-578,2022.
Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, North K, Church SE, Fraietta JA, Chang WJ, Lacey SF, Lu XM, Zhang Y, Whig K, Schultz DC, Cherry S, Gerson J, Schuster SJ, Porazzi P, Ruella M.: Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer Cancer Discov 12 : 2372-2391,2022.
Sharma A, Farnia S, Otegbeye F, Rinkle A, Shah J, Shah NN, Gill S, Maus MV.: Nomenclature for Cellular and Genetic Therapies: A Need for Standardization Transplant Cell Ther : 2022.
Diorio C, Shraim R, Myers R, Behrens EM, Canna S, Bassiri H, Aplenc R, Burudpakdee C, Chen F, DiNofia AM, Gill S, Gonzalez V, Lambert MP, Leahy AB, Levine BL, Lindell RB, Maude SL, Melenhorst JJ, Newman H, Perazzelli J, Seif AE, Lacey SF, June CH, Barrett DM, Grupp SA, Teachey DT.: Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19 Clin Cancer Res 28 : 3804-3813,2022.
Saygin C, Roloff GW, Hahn CN, Chhetri R, Gill SI, Elmariah H, Talati C, Nunley E, Gao G, Kim A, Bishop MR, Kosuri S, Das S, Singhal D, Venugopal P, Homan CC, Brown AL, Scott HS, Hiwase DK, Godley LA.: Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies Blood Adv 7 : 549-554,2022.
Academic Contact Information
Room 8-101
Smilow Translational Research Center
3400 Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-573-4015
Patient appointments: 800-789-7366